Delivra Health Brands Inc. (DHB:CA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company showed strong financial performance with 8% revenue growth and maintained a 51% gross margin despite challenges. Positive adjusted EBITDA for three consecutive years and strategic global expansion plans support a positive outlook. The lack of Q&A does not affect the positive sentiment, as the earnings call highlights growth, resilience, and strategic initiatives. The absence of a market cap makes it challenging to predict the exact stock price movement, but the overall sentiment leans towards a positive reaction over the next two weeks.
Key Financial Performance
Revenue Growth 8% year-over-year revenue growth in fiscal 2025, despite revamping the LivRelief Infused business unit. This growth was driven by double-digit growth in the Dream Water brand across retail and e-commerce in Canada and the U.S., as well as double-digit e-commerce growth for LivRelief Canada.
Gross Margin Maintained a 51% gross margin despite rising input costs, global instability, and unfavorable changes in channel mix. This demonstrates operational discipline and resilience.
Adjusted EBITDA Achieved positive adjusted EBITDA for the third consecutive year, even with increased investments in marketing, sales, and product innovation.
Inventory Growth Increased inventory by more than 86% (approximately $1.3 million) to support future growth without additional funding. This reflects improved liquidity and working capital positions.
U.S. and International Retail Growth Retail and international channels grew by 17% in the U.S., driven by new innovations like immunity and gummies, and additional distribution points in the airport travel channel.
E-commerce Growth Double-digit growth in the e-commerce channel in Canada for both LivRelief and Dream Water brands, despite cost pressures from manufacturing partners and Amazon.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: Achieved 8% year-over-year revenue growth in fiscal 2025, driven by Dream Water's double-digit growth in Canada and the U.S. across retail and e-commerce.
Product Innovation: Dream Water is set to launch new functional extensions focused on immunity, beauty, and enhanced sleep formulations. LivRelief is advancing science-backed topical innovations for pain and wellness.
Retail and E-commerce Expansion: Expanded distribution with major retail and e-commerce partners across North America, including Circle K, 7-Eleven, Casey's, Loblaws, Sobeys, Shoppers Drug Mart, and others. Achieved double-digit growth in these channels.
Global Expansion: Established a foundation in North America and expanded into the Middle East, with plans for further expansion into Latin America and Europe.
Gross Margin: Maintained a 51% gross margin despite rising input costs and challenges in the LivRelief Infused channel.
Adjusted EBITDA: Reported positive adjusted EBITDA for the third consecutive year, demonstrating operational discipline and resilience.
Strategic M&A: Positioned to pursue selective accretive acquisitions targeting profitable wellness brands that align with the company's focus.
Marketing and Awareness: Invested in campaigns like 'Shush Your Mind' for Dream Water and 'Quiets Chronic Pain' for LivRelief, with plans to expand into new media, influencer channels, and strategic partnerships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Reorganizing LivRelief Infused route to market: The company is facing challenges in building a more controlled and profitable business model for its LivRelief Infused business unit.
Rising input costs: The company is managing increasing costs of raw materials and manufacturing, which could impact profitability.
Global instability: Uncertain global conditions are posing risks to the company's operations and market stability.
Competitive landscape: The company faces intense competition, particularly as a market leader, which could pressure market share and margins.
Cost pressures from manufacturing partners and supply chain: The company is experiencing cost pressures from its manufacturing partners and supply chain, which could affect operational efficiency and profitability.
Challenges in Infused LivRelief channel: The company is dealing with unfavorable changes in the channel mix and cost pressures, including those from platforms like Amazon.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects better results in fiscal 2026, building on a compound annual growth rate of 13% over the past four years. The company is targeting continued growth in retail and international channels, particularly in the U.S. and Middle East.
Gross Profit Margin: The company aims to maintain and grow gross profit margins at 50% or higher, despite cost pressures from manufacturing partners and unfavorable channel mix changes.
Adjusted EBITDA: The company anticipates improved adjusted EBITDA in fiscal 2026, marking its fourth consecutive year of positive EBITDA.
Global Expansion: Plans to expand into Latin America and Europe, leveraging early success in the Middle East. This is described as a scalable, asset-light growth opportunity.
Innovation Pipeline: Dream Water will launch new functional extensions focused on immunity, beauty, and enhanced sleep formulations. LivRelief will advance science-backed topical innovations for pain and wellness.
Strategic M&A: The company is in a position to pursue selective accretive acquisitions targeting profitable or near-profitable wellness and better-for-you brands.
Marketing and Awareness: Plans to expand into new media, influencer channels, and strategic partnerships to strengthen consumer awareness and credibility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:There were no questions asked during the Q&A session, as confirmed by the operator. Therefore, no direct answers or management responses were provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brands Inc
Brands margin
CEO Delivra
Canada
Delivra Health
Gord President
Health Brands
LivRelief
President CEO
USA
acquisition
awareness
brand
category
challenge
channel
consumer
convenience
date hereof
demand
digit
driver
estimate
expansion
investment
marketing
offer
partner
partnership
product
profitability
retail commerce
retailer
security
shareholder value
stage
wellness
ABVX Transcript
Delivra Health Brands Inc. (DHB:CA) Q4 2025 Earnings Call Transcript
Positive10-6
The company showed strong financial performance with 8% revenue growth and maintained a 51% gross margin despite challenges. Positive adjusted EBITDA for three consecutive years and strategic global expansion plans support a positive outlook. The lack of Q&A does not affect the positive sentiment, as the earnings call highlights growth, resilience, and strategic initiatives. The absence of a market cap makes it challenging to predict the exact stock price movement, but the overall sentiment leans towards a positive reaction over the next two weeks.
ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript
Unknown4-8
The earnings call reveals a mixed sentiment. Positive aspects include a strong cash position and successful fundraising, which support financial sustainability and strategic goals. However, concerns about enrollment challenges, patient discontinuation due to side effects, and regulatory risks temper the outlook. The Q&A session highlighted management's reluctance to provide specifics on future data readouts and pipeline prioritization, adding uncertainty. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
ABVX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
